Ravens' running game was crucial in a big win over the Chargers, especially on 4th downDIRTT Welcomes Holly Hess Groos to the Board of Directors
Ravens' running game was crucial in a big win over the Chargers, especially on 4th down
Billionaire property tycoon Nick Candy said he would take up the fundraising role in the new year. Holly Valance’s husband is to become Reform UK’s treasurer, after renouncing his Conservative Party membership over what he described as “too many broken promises.” Billionaire property tycoon Nick Candy accused the Tories of a “complete breach of trust with the wealth creators in our country” and said he would take up the fundraising role in the new year. Ms Valance is also a prominent Reform backer. The Australian-British actress and singer was pictured with her husband, Donald Trump and party leader Nigel Farage at the US president-elect’s Mar-a-Lago resort in 2022. Reform has been buoyed by a series of Tory defections, including former minister Andrea Jenkyns, and described Mr Candy’s appointment as its “latest coup” as it prepares for the local elections in May. Mr Candy said: “I have today resigned my membership of the Conservative Party after many years of active support and substantial donations to the party. “I am sorry to say there have been too many broken promises and a complete breach of trust with the wealth creators in our country. “Nigel Farage is a close personal friend of mine, and Reform UK represents the future of British politics. “I am pleased to announce that I will now become the treasurer for Reform UK and intend to raise enough funds for them to win the next general election. “I will take up the role in the new year.” Reform leader Nigel Farage MP said: “I warmly welcome this decision. We are the fastest-growing movement in British politics today and Nick’s efforts will help Reform UK transform our country.”inter has already arrived across the nation and it is necessary to have items to protect against the cold weather. That's why here are the items every retiree should have at home to prepare and be ready for this time of year. Cold weather is approaching and it's time to start stocking up on winter supplies. As the cold season approaches, retirees can and should head to to stock up on inexpensive essentials. Dollar Tree, the ideal store for retirees and receptionist at AZ Health Insurance Brokers, believes that is the ideal place to buy batteries. With shorter days and possible power outages, it's important to have a good supply of batteries on hand. At just $1.25 per pack, it's a no-brainer to buy several packs to be ready for winter. Dollar Tree has great options for the winter chill Dollar Tree cookies are a delight to the palate and the pocket Woroch also suggests stocking up on holiday cookie tins. "They are a great way to package your favorite seasonal homemade treats," she said. "You can give them as gifts to your loved ones, teachers, neighbors and hosts at an affordable price without feeling stingy!" These versatile containers are perfect for holiday gift-giving and can be reused for year-round storage. Dollar Tree is ideal for holiday shopping for retirees Starting Christmas shopping early is always a good idea, and Woroch suggests buying stocking stuffers at Dollar Tree. She recommends "an assortment of small toys, lip gloss, hair ties, craft items, crayons and sticker booklets." As she notes, "This is an easy thing I can check off my holiday shopping list in advance and know I'll have it ready when it's time to stuff the Christmas stockings."Semiconductor designer Advanced Micro Devices ( AMD 0.10% ) has been swooning lately. Despite a robust price jump last Monday, AMD's stock is down more than 40% from its one-year high. With less than a week left in 2024, share prices have plunged 15% this year. Meanwhile, the S&P 500 (SNPINDEX: ^GSPC) stock market index gained 25% year to date. Is AMD missing out on the artificial intelligence (AI) market boom , or is the stock a fantastic AI investment at these lower prices? On further review, a third option looks more correct -- AMD is a "hold" in my book. AMD's modest AI market share growth Archrival Nvidia ( NVDA -2.09% ) is setting the standard for AI accelerator chips and how they are used in actual computing systems, but AMD is a leading challenger to that company's dominant position. In October's third-quarter report, AMD's data center sales rose 122% year over year to $3.5 billion. The Instinct series of AI accelerators and EPYC line of server-grade processors drove this surge, and both products play important roles in training and operating large language models (LLMs) . Granted, AMD's data center sales can't hold a candle to Nvidia's $30.8 billion in the same quarter. That's not the end of the world, though. AMD is embracing its underdog role. The company isn't trying to set new AI standards. Instead, it makes sure its products work with the same AI software and programming techniques as Nvidia's chips. Simplifying the switch from one hardware solution to another makes it easier to win over existing Nvidia users to AMD's alternatives. "Pretty much any model written for the standard framework, if you're running on NVIDIA, you could run it on [AMD Instinct] MI300 out of the box, day 1, and it would work," AMD's Forrest Norrod said at a recent industry conference. And this strategy is paying dividends . AMD's data center growth outpaced Nvidia's 112% annual increase in the third quarter. In other words, AMD is gaining some ground on the larger AI chip specialist. Has the AI boom peaked? AMD is a significant provider of AI hardware. It's not all wine and roses, though. The soaring AI bandwagon may have surged a bit too far and too fast, and investors are taking a more critical look at this boom from a long-term perspective. As a result, many stocks in the AI sphere have stalled or even fallen recently. Nvidia shares are up a measly 0.1% in the last month, and OpenAI partner Microsoft gained just 0.6% in the same period. Leading AI system builders Super Micro Computer and Dell dropped 7.1% and 17.2%, respectively. And maybe it's all for the best. With the exception of Supermicro's scandal-stricken profile, none of these stocks are cheap, even after their recent price corrections . AMD has emerged as a particularly expensive option, even in comparison to notorious market darlings like Microsoft and Nvidia: Valuation Metric AMD Nvidia Microsoft Price to earnings (P/E) 112 54 36 Price to free cash flow (P/FCF) 131 58 43 Data was collected from Finviz on Dec. 28, 2024. Buy AMD with caution if you do anything at all AMD's drooping stock chart may be painful for current shareholders, but investors looking to put more of their cash to work in the market should celebrate the lower buy-in prices. In fact, AMD's volatile stock could benefit from an even sharper price correction. Right now, the best approach to AMD's stock might be a risk-mitigation plan, such as buying in thirds or setting up a dollar-cost averaging plan . Either method can help you work around price-dip risks by grabbing more shares when they're cheap and fewer when they're pricy. That's a prudent approach when share prices are high and the direction of short-term moves is unpredictable. At the moment, I wouldn't get into AMD's stock without these robust price controls. Long story short, I wouldn't sell AMD stock today, and I would buy it only with great caution. The third option is to simply hold the stock and not make any active moves. Most AMD investors should probably not touch this stock's buy or sell buttons until it either cools down or connects to a stronger business trend.
Glycated Albumin Assay Market New Trends, Size, Share, Top Companies, Industry Analysis, Advance Technology, Future Development & Forecast - 2028 12-13-2024 07:50 PM CET | Health & Medicine Press release from: ABNewswire The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China). Browse 70 market data Tables and 33 Figures spread through 126 Pages and in-depth TOC on "Glycated Albumin Assay Market by Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User (Hospitals & Diabetic Care Center, Diagnostic Laboratory) & Region (North America, Europe, APAC, Latin America, & MENA) - Global Forecast to 2028 Glycated Albumin Assay Market [ https://www.marketsandmarkets.com/Market-Reports/glycated-albumin-assay-market-265553363.html?utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] in terms of revenue was estimated to be worth $0.2 billion in 2023 and is poised to reach $0.3 billion by 2028, growing at a CAGR of 8.9% from 2023 to 2028 according to a new report by MarketsandMarkets Trademark . Government assistance is stimulating the market. Players in the glycated albumin assay market have significant potential in developing nations like India and Japan. Additionally, the aging population in developed and developing nations would favorably impact the market for glycated albumin assay. The prevalence of age-related illnesses like diabetes and pancreatic disorders is anticipated to rise dramatically as the senior population is forecast to grow quickly. Numerous test prescriptions to assess the levels of creatinine, albumin, glucose, ketones, and bilirubin are caused by diagnosing and treating such disorders, which is driving the market's expansion. Browse through 100 market data tables and 44 figures spread across 180 pages and the in-depth TOC of the glycated albumin assay market. Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=265553363 [ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=265553363&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] The type 2 diabetes segment accounted for the largest share of the glycated albumin assay market, by application segment, in 2022 Based on application, the glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. The type 2 diabetes segment accounted for the largest share of the glycated albumin assay market, mainly due to increased focus on type 2 diabetes care and increased funding for diagnostic research. Hospitals and diabetes care centers segment to register the highest growth rate during the forecast period The significant market share of this sector is mostly due to an increased emphasis on early disease diagnosis. Additionally, hospitals and diabetes care facilities are committed to providing patients with diabetes-specialized care. Their focus on comprehensive diabetes care makes them primary locations for conducting glycated albumin assays, which are important diagnostic tests for monitoring glycemic control. North America is the largest regional market during the forecast period North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the five main geographic segments of the worldwide glycated albumin assay market. In 2022, the glycated albumin assay market's largest regional market was North America. The government's support for regional research and increased funding for the creation of preventive care diagnostics can be used to explain North America's significant market dominance. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=265553363 [ https://www.marketsandmarkets.com/requestsampleNew.asp?id=265553363&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] Glycated Albumin Assay Market Dynamics: Drivers: * Rising prevalence of diabetes Restraints: * Unfavorable reimbursement scenario Opportunities: * Rising investments in healthcare and life sciences research Challenges: * Changing regulatory landscape Key Market Players: The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China). Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=265553363 [ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=265553363&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr ] Glycated Albumin Assay Market Advantages: * Early Glycemic Control Assessment: Glycated albumin testing provides an early and accurate assessment of glycemic control. Unlike HbA1c, which reflects long-term glucose levels, glycated albumin measurements reflect shorter-term changes in blood glucose levels, typically over the preceding two to three weeks. This allows for timely intervention and adjustment of treatment plans, enabling healthcare providers to optimize diabetes management and reduce the risk of complications. * Sensitivity to Glycemic Variability: Glycated albumin assays are highly sensitive to glycemic variability. They can detect rapid fluctuations in blood glucose levels, providing a more dynamic representation of glycemic control. This sensitivity is particularly important for patients with conditions such as gestational diabetes, diabetes in children, and those with brittle diabetes who experience wide fluctuations in blood sugar levels. * Independence from Hemoglobin Variants: Unlike HbA1c, which can be affected by hemoglobin variants and conditions like anemia, glycated albumin measurements are not influenced by these factors. This independence ensures more accurate and reliable results, eliminating potential confounding factors and allowing for consistent monitoring of glycemic control across different patient populations. * Rapid Turnaround Time: Glycated albumin assays offer rapid turnaround times compared to other glycemic control markers. Results can be obtained within hours, providing timely information for clinical decision-making. This quick feedback is particularly valuable in emergency situations, postprandial monitoring, and for assessing treatment efficacy in real-time. * Personalized Medicine Approach: The glycated albumin assay supports a personalized medicine approach to diabetes management. It allows for individualized treatment plans based on a patient's unique glycemic patterns, helping to optimize therapies and achieve better glycemic control. This personalized approach can lead to improved patient outcomes and quality of life. * Integration with Digital Health Solutions: The glycated albumin assay can be integrated with digital health solutions and electronic medical records, enabling seamless data management and analysis. This integration facilitates remote monitoring, data sharing between healthcare providers and patients, and the generation of personalized reports and trends, enhancing patient engagement and self-management. * Market Growth Potential: With the increasing prevalence of diabetes worldwide, the glycated albumin assay market has substantial growth potential. The demand for accurate and reliable glycemic control monitoring tools is rising, driven by the need for effective diabetes management, early intervention, and risk reduction. This market growth presents opportunities for innovation, technological advancements, and improved accessibility of glycated albumin testing. In summary, the glycated albumin assay market offers advantages such as early glycemic control assessment, sensitivity to glycemic variability, independence from hemoglobin variants, rapid turnaround time, personalized medicine approach, integration with digital health solutions, and significant growth potential. These advantages contribute to the growing importance of glycated albumin assays in diabetes management and highlight their potential to improve patient care and outcomes. Media Contact Company Name: MarketsandMarkets Trademark Research Private Ltd. Contact Person: Mr. Rohan Salgarkar Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=glycated-albumin-assay-market-new-trends-size-share-top-companies-industry-analysis-advance-technology-future-development-forecast-2028 ] Phone: 18886006441 Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 City: Florida State: Florida Country: United States Website: https://www.marketsandmarkets.com/Market-Reports/glycated-albumin-assay-market-265553363.html This release was published on openPR.Jimmy Carter’s public service heralded by Southern California lawmakers on either side of the aisle
A RESORT-HOTEL casino has sold 250,000 shares of the parent’s stock at market price, “as a reward” to “loyal patrons.” This was learned from a recent filing by the parent company to the Philippine Stock Exchange. Bloomberry Resorts and Hotels Inc. sold the 0.25 million shares at P4.57 each earlier this month. The total was just over P1.14 million. “These shares shall be given as a reward to Solaire’s loyal patrons and as part of Solaire’s marketing program,” the Bloomberry group said. The Bloomberry group developed and operates Solaire Resort & Casino at Entertainment City in Parañaque. In May this year, the group launched a new casino complex, Solaire Resort North, at Vertis, Quezon City. Australian casino industry veteran Greg Hawkins, the Bloomberry Resorts executive in charge of Solaire North, was named as acting chief operating officer (COO) of Bloomberry Resorts and Hotels last week. Hawkins was appointed following the resignation of Thomas Arasi as group president and chief operating officer. Rizal Raoul S. Reyes has covered technology, science, business, property and special reports. He had working stints with the Business Star, Manila Bulletin and Independent Daily News.
Timo Meier hit Martin Necas with a brutal knee-on-knee play on Saturday night, but despite the ejection, he doesn't appear to be facing any more discipline even with some calling for a multiple game suspension on the play. Saturday night's game between the New Jersey Devils and Carolina Hurricanes was their second in as many nights, and unsurprisingly, things got fairly heated throughout the game as Carolina pulled out a huge victory over their fierce Metropolitan Division rivals. Perhaps the biggest reason for that was the hit from Timo Meier that resulted in a major penalty and a game misconduct, as he took down superstar forward Martin Necas with a knee-on-knee hit. This hit looked ugly on first viewing, but thankfully Necas was okay and didn't miss a shift in the game, although many believed that given Meier's actions earlier in the year, a suspension could potentially be on the horizon. However, ESPN's Greg Wyshynski has now confirmed that Meier won't face any further discipline for his part in the play, with the Hurricanes ultimately picking up the win on the back of this play. Some fans believe that this was all down to embellishment from Necas, who hasn't been known to do that throughout his young NHL career, but without missing a shift, it's easy to see why people believe that. However, others see the play as a very dangerous one and believe that Necas was lucky to walk away without an injury, especially given the force that Meier put into the play. Ultimately, any play where this type of collision occurs can lead to serious injury, so thankfully no one involved was hurt, but it appears that the league have made the right call by not handing out any further discipline to the Devils veteran. This article first appeared on Blade of Steel and was syndicated with permission.
Ancient tablet carved with Ten Commandments set for auction
(The Center Square) – U.S. Rep. Andy Biggs, R-Arizona, blasted U.S. Citizenship and Immigration Services Director Ur Jaddou for her agency approving illegal border crossers as sponsors for illegal border crossers. At a U.S. House Judiciary subcommittee hearing , Biggs also pointed out that the sponsors were found to be committing Social Security and other fraud under her watch. Biggs addressed rampant fraud in a program created by Department of Homeland Security Secretary Alejandro Mayorkas for inadmissible citizens of Cuba, Haiti, Nicaragua and Venezuela, who don’t qualify for admission into the U.S. Under Mayorkas, they were flown into the country through a CHNV parole program, used a CBP One phone app to apply for entry, and were released into the country. Part of the process requires having a “supporter” fill out an application on behalf of the CHNV parolee. While Mayorkas claimed app user parolees and supporters were thoroughly vetted, multiple Office of Inspector General reports disproved this claim, expressing security risks at airports. In August, flights of CHNV illegal border crossers were temporarily suspended after a USCIS internal review found that tens of thousands of CHNV fraudulent applications were processed. Supporters used fake Social Security numbers and phone numbers and listed the same physical address on nearly 20,000 applications, according to the report, The Center Square reported . Biggs asked Jaddou if she disputed the fact that supporters used the same Social Security Number on CHNV applications, which “happened at least 3,200 times. The same phone number used at least 3,300 times. The same supporter email address was used on applications nearly 2,000 times.” Jaddou said she didn’t have the report in front of her and didn’t dispute it. “You don’t really want to admit there’s this much rampant fraud,” he said. Biggs next cited examples of fraud that weren’t fixed. “The same exact 184-word response was used on more than 1,800 applications by nearly 194 CHNV supporters,” he said. “More than 460 nonexistent zip codes were used on supported applications on behalf of more than 2,800 CHV aliens. You can dance around and say you don't have the report in front of you, but these are the facts. This program is rife with fraud.” As of Aug. 6, DHS had approved more than 80,000 CHNV supporters for the program who were in the U.S. on a temporary basis. USCIS approved 224 CHNV parolees who were already in the country illegally as sponsors for CHNV parolees that came after them, meaning illegal foreign nationals were sponsoring illegal foreign nationals. USCIS also approved 28,322 illegal foreign nationals shielded from deportation through Temporary Protected Status as CHVN supporters; “19,865 SLEs approved as CHNV supporters, 311 DACA recipients approved as CHNV supporters, 1,300-plus aliens in the U.S. on temporary visas approved as CHNV supporters, 64 refugees approved as CHNV supporters, 19,112 conditional permanent residents approved this season as CHNV supporters,” he said. “That is the program that you are administering. I'm not talking the aliens. I'm not getting into the violation of law of the U.S. code 1182, which states that the use of parole is supposed to be a case-by-case basis.” Biggs said the supporter application process was so rampant with fraud that it was temporarily shut down but wasn’t fixed. The fraud is “still ongoing. We're waiting for the next report to confirm that these things are still going on,” he said. In addition to the USCIS report, a U.S. House Committee on Homeland Security investigation found that "as of mid-October 2023, there were 1.6 million inadmissible aliens awaiting travel authorizations through the CHNV program” and DHS was using 50 airports worldwide to fly them in, The Center Square reported . None flown into the country have a legal basis to enter the U.S. before being paroled through the CHNV program, DHS documents the committee obtained state. "All individuals paroled into the United States are, by definition, inadmissible, including those paroled under the CHNV processes," one of the DHS documents states. The CHNV parole program was among more than a dozen that House Republicans identified as illegal and cited as reasons to impeach Mayorkas. According to the latest U.S. Customs and Border Protection data , more than 852,000 illegal foreign nationals were processed and released into the country through the CBP One App and more than 531,000 Cubans, Haitians, Nicaraguans, and Venezuelans deemed inadmissible were released into the country through the CHNV parole program, as of October. Under the Biden administration, more than three million illegal border crossers were reported from CHNV countries, The Center Square reported . Many have been directly linked to violent crimes committed against Americans, The Center Square reported .